Axillary Hyperhidrosis Treatment Market Trends, Regulations And Competitive Landscape Outlook to 2027

Axillary hyperhidrosis is characterized by excessive sweating, primarily in the armpits. Axillary hyperhidrosis arises due to genetic causes or physical and emotional stress and family history exists in approximately 30% of the cases. According to American Academy of Dermatology, Axillary hyperhidrosis affects 3% of the population in the U.S. Axillary hyperhidrosis begins in the childhood or in adolescence. Even though Axillary hyperhidrosis is primarily a physical burden, it may deteriorate quality of life by affecting work and social life and causes significant physiological distress. Patients with axillary hyperhidrosis sweat five times the amount needed to regulate body temperature. However, treatment for axillary hyperhidrosis is readily available and involves topical oral as well as surgical treatment. Choice of treatment depends on severity and affordability, as majority of treatment do not involve reimbursement except surgical treatment. Under CMS (Center for Medicare and Medicaid Services) only 3 treatments with Botulinum toxin A are reimbursed in a year. Topical treatment with antiperspirant solutions such as Driclor (aluminium chloride hexahydrate), corticosteroid creams etc. are recommended in mild cases. Subcutaneous injection of Botulinum toxin A is recommended in severe cases. Endoscopic thoracic sympathectomy (ETS) is rarely recommended due to less effectiveness of treatment and availability of better alternatives.

Axillary Hyperhidrosis Market: Drivers and Restraints

Global axillary hyperhidrosis is the common condition and can tend to chronic condition. However, the severity diminishes in the older adult life. Growing prevalence of axillary hyperhidrosis is the primary factor driving the growth of the global market. According to International Hyperhidrosis Society study results, 2.8% of the U.S. population is affected with primary hyperhidrosis and over 50% of them suffer from axillary hyperhidrosis. However, low treatment rate and limited reimbursement are the factors expected to limit the growth of global axillary hyperhidrosis treatment market over the forecast period of 2017–2027. According to survey results from International Hyperhidrosis Society, only 38% of the patients visited their healthcare professionals for their excessive sweating problem.

Axillary Hyperhidrosis Market: Segmentation: Axillary Hyperhidrosis Treatment Market Segmentation By Treatment – Topical Treatments(Topical Creams & Solutions (E.G. Driclor), Botulinum Toxin Type A (Botox) Injections), Oral Pills(Anticholinergic (E.G. Oxybutynin, Glycopyrrolate, Propantheline Bromide), Propranolol, Clonazepam), Non-Surgical Microwave Energy Destruction Of Sweat Glands, Endoscopic Thoracic Surgery (ETS); By Distribution Channel – Hospital Pharmacy, Retail Pharmacy, Drug Stores, Online Prescription Stores

Axillary Hyperhidrosis Market: Overview: On the basis of treatment, topical treatment segment is expected to contribute high revenue share to global axillary hyperhidrosis treatment. Among oral medications for axillary hyperhidrosis treatment, anticholinergic tablets are most frequently prescribed.  Emerging new techniques such as non-surgical microwave energy destruction of sweat glands using miraDry technology would further flourish the volume for axillary hyperhidrosis treatment market over the forecast period of 2017–2027. Many other treatment procedures are being studied in the clinical trials, which are expected to launch during the forecast period. For instance, Ulthera, Inc. is evaluating Ulthera system – a microfocused ultrasound system for destruction of sweat glands. Candela Corp. in collaboration with is developing diode laser treatment device for axillary hyperhidrosis treatment Success of these treatment options depends on the acceptance by the physicians and adoption of treatment by patients.

Axillary Hyperhidrosis Market: Regional Overview: Geographically, the global axillary hyperhidrosis treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is expected to lead the global axillary hyperhidrosis market due to high prevalence. In 2014, 1.3 Mn population in the U.S. was suffering from axillary hyperhidrosis in the U.S. Moreover, extensive clinical trials in the region would further accelerate the market growth. Asia Pacific axillary hyperhidrosis market is expected to witness delayed growth due to lack of knowledge on advanced treatment options

Axillary Hyperhidrosis Market: Key Players: Some of the key players identified in global axillary hyperhidrosis market are GlaxoSmithKline Plc., Allergan Inc. Miramar Labs, Inc., Ulthera, Inc., Candela Corp., Dr. August Wolff GmbH & Co. KG Arzneimittel, Nuvisan GmbH, FGK Clinical Research GmbH, etc. among others.

Request Report Sample@